Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | SDHB | P21912 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | RGS4 | P49798 | 1/20 | 0.48 |
| ▸ | RGS8 | P57771 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445065 | 0.93 | SDHB (0.54) | SDHBKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL5435867 | 0.87 | SDHB (0.50) | SDHBALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL5448579 | 0.87 | MEN1 (0.56) | SDHBRGS4KDM4EALDH1A1MAPT | |
| SCHEMBL5439611 | 0.86 | GSK3A (0.47) | CNR1CNR2RGS4RGS8KDM4E | |
| SCHEMBL5196104 | 0.86 | SDHB (0.49) | SDHBMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5197153 | 0.86 | SDHB (0.49) | CNR1CNR2SDHBMAPTKMT2A | |
| SCHEMBL5445050 | 0.86 | HRH3 (0.55) | SDHBKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL5445058 | 0.85 | SDHB (0.54) | SDHBALDH1A1CMA1GRM2 | |
| SCHEMBL5443008 | 0.85 | SDHB (0.49) | CNR1CNR2SDHBMAPT | |
| SCHEMBL5444680 | 0.85 | SDHB (0.57) | SDHBALDH1A1MAPTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | claimed |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8399493-B2 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | CNR1 31/4885CNR2 29/4885SDHB 1074/4885 |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRIA2 | CNR1 45/4885CNR2 28/4885SDHB 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.